

DOCKET NO.: PH-7064/BMS-0685  
Application No.: 09/783,248  
Office Action Dated: April 29, 2004

PATENT  
REPLY FILED UNDER EXPEDITED  
PROCEDURE PURSUANT TO  
37 C.F.R. § 1.116

**Amendments to the Specification:**

*Please replace the paragraph on page 92, beginning at line 1 with the following:*

The most preferred technetium radiopharmaceuticals of the present invention are comprised of a hydrazido or diazenido bonding unit and two types of ancillary designated  $AL_1$  and  $AL_2$ , or a diaminedithiol chelator. The second type of ancillary ligands  $AL_2$  are comprised of one or more soft donor atoms selected from the group: phosphine phosphorus, arsine arsenic, imine nitrogen ( $sp^2$  hybridized), sulfur ( $sp^2$  hybridized) and carbon ( $sp$  hybridized); atoms which have p-acid character. Ligands  $AL_2$  can be monodentate, bidentate or tridentate, the denticity is defined by the number of donor atoms in the ligand. One of the two donor atoms in a bidentate ligand and one of the three donor atoms in a tridentate ligand must be a soft donor atom. We have disclosed in co-pending U.S. Patent No. 5,744,122, and U.S. Patent Application Serial No. 60/013360, now US-B-5,879,659, and ~~U.S. Patent Application Serial No. 08/646,886~~, the disclosures of which are herein incorporated by reference in their entirety, that radiopharmaceuticals comprised of one or more ancillary or co-ligands  $AL_2$  are more stable compared to radiopharmaceuticals that are not comprised of one or more ancillary ligands,  $AL_2$ ; that is, they have a minimal number of isomeric forms, the relative ratios of which do not change significantly with time, and that remain substantially intact upon dilution.